留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

肿瘤干细胞的治疗耐受机制研究进展

曹梦雪 孙凡 林厚文

曹梦雪, 孙凡, 林厚文. 肿瘤干细胞的治疗耐受机制研究进展[J]. 药学实践与服务, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
引用本文: 曹梦雪, 孙凡, 林厚文. 肿瘤干细胞的治疗耐受机制研究进展[J]. 药学实践与服务, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
Citation: CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001

肿瘤干细胞的治疗耐受机制研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.001
基金项目: 国家青年科学基金资助项目(81502936)

Advance in resistance mechanism of cancer stem cells therapy

  • 摘要: 肿瘤的发病率和死亡率位居各类疾病之首,肿瘤的复发和转移是目前肿瘤治疗失败的主要原因,肿瘤治疗的失败又与肿瘤干细胞有着密切的关系。肿瘤干细胞的耐药机制一般包括以下几个方面:高表达的ABC转运蛋白介导化疗药物外排;乙醛脱氢酶的高表达与肿瘤的发病率和预后差显著相关;高效的DNA损伤修复能力;促存活通路的激活能力。笔者综合介绍肿瘤干细胞几种主要的治疗耐受机制,以期为开发新型抗肿瘤药物以及临床合理用药提供理论依据。
  • [1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J].Cell, 2011, 144 (5): 646-674.
    [2] Chufan EE, Kapoor K, Ambudkar SV. Drug-protein hydrogen bonds govern the inhibition of the ATPhydrolysis of the multidrug transporter P-glycoprotein[J].Biochem Pharmacol, 2016, (101): 40-53.
    [3] Guan GF, Zhang DJ, Zheng Y,et al. Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma[J].Oncol Lett, 2015, 10 (2): 631-636.
    [4] Xie ZY, Lv K, Xiong Y,et al. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer[J]. Oncol Res Treat, 2014, 37 (11): 666-672.
    [5] Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance[J]. Mol Pharmacol, 2013, 84 (5): 655-669.
    [6] Schexnayder C, Stratford RE. Genistein and Glyceollin effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells[J]. Int J Environ Res Public Health, 2015, 13 (1):17-30.
    [7] Hu J, Zhang X, Wang F, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo[J]. Oncotarget, 2015, 6 (42): 44643-44659.
    [8] Zhou Q, Ye M, Lu Y,et al. Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells[J]. PLoS One, 2015, 10 (8): e0136694.
    [9] Rodriguez-Torres M, Allan AL. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors[J]. Clin Exp Metastasis, 2016, 33 (1): 97-113.
    [10] Qiu Y, Pu TJ, Guo P, et al. ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome[J]. Exp Mol Pathol, 2016, (100): 145-150.
    [11] Moreb JS, Baker HV, Chang LJ,et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells[J]. Mol Cancer, 2008, 7 (87). doi:  10.1186/1476-4598-7-87.
    [12] Mizuno T, Suzuki N, Makino H,et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species[J]. Gynecol Oncol, 2015, 137 (2): 299-305.
    [13] Diehn M, Cho RW, Lobo NA,et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells[J]. Nature, 2009, 458 (7239): 780-783.
    [14] Ajani JA, Wang X, Song S,et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients[J]. Mol Oncol, 2014, 8 (1): 142-149.
    [15] Mi JQ, Li JM, Shen ZX,et al. How to manage acute promyelocytic leukemia[J]. Leukemia, 2012, 26 (8): 1743-1751.
    [16] Parajuli B,Fishel ML,Hurley TD.Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells[J].J Med Chem,2014,57 (2):449-461.
    [17] Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy[J]. Cell Death Differ, 2012, 19 (5): 768-778.
    [18] Chen Y, Li D, Wang D,et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells[J]. J Cell Biochem, 2012, 113 (12): 3643-3652.
    [19] Al-Assar O, Mantoni T, Lunardi S,et al. Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2fraction[J]. Cancer Biol Ther, 2014, 11 (12): 1028-1035.
    [20] Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer[J]. Cancer Res, 2008, 68 (12): 4674-4682.
    [21] Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response[J]. Nature, 2006, 444 (7120): 756-760.
    [22] Yin H, Glass J. The phenotypic radiation resistance of CD44+/CD24-/low breast cancer cells is mediated through the enhanced activation of ATM signaling[J]. PLoS One, 2011, 6 (9): e24080.
    [23] Teng Y, Wang X, Wang Y,et al. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2010, 392 (3): 373-379.
    [24] Wang Y, Krivtsov AV, Sinha AU,et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML[J]. Science, 2010, 327 (5973): 1650-1653.
    [25] Martins-Neves SR, Paiva-Olivira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling[J]. Cancer Lett, 2016, 370 (2): 286-295.
    [26] Catalano V, Dentice M, Ambrosio R,et al. Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling[J]. Cancer Res, 2015, 76 (5): 1237-1244.
    [27] Fang L, Zhu Q, Neuenschwander M,et al. A small-molecule antagonist of the beta-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis[J]. Cancer Res, 2015, 76 (4): 891-901.
    [28] Wang X, Ma Z, Xiao Z,et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells[J]. Oncol Rep, 2012, 28 (6): 2247-2254.
    [29] Liu YP, Yang CJ, Huang MS,et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling[J]. Cancer Res, 2013, 73 (1): 406-416.
    [30] Mcauliffe SM, Morgan SL, Wyant GA,et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy[J]. Proc Natl Acad Sci USA, 2012, 109 (43): 2939-2948.
    [31] Xie M, Zhang L, He CS,et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells[J].J Cell Biochem, 2012, 113 (5): 1501-1513.
    [32] Mabertk, Cojoc M, Peitzsch C,et al. Cancer biomarker discovery: current status and future perspectives[J]. Int J Radiat Biol, 2014, 90 (8): 659-677.
    [33] Fischer M, Yen WC, Kapoun AM,et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations[J]. Cancer Res, 2011, 71 (5): 1520-1525.
    [34] Noman AS, Uddin M, Rahman MZ,et al. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh[J]. Sci Rep, 2016, 6:18830.
    [35] Xu M, Gong AH, Yang HQ, et al. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44+ Musashi-1+ gastric cancer stem cells[J]. Cancer Lett, 2015, 369 (1):124-133.
  • 加载中
计量
  • 文章访问数:  2537
  • HTML全文浏览量:  237
  • PDF下载量:  917
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-02-05
  • 修回日期:  2016-06-15

肿瘤干细胞的治疗耐受机制研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.001
    基金项目:  国家青年科学基金资助项目(81502936)

摘要: 肿瘤的发病率和死亡率位居各类疾病之首,肿瘤的复发和转移是目前肿瘤治疗失败的主要原因,肿瘤治疗的失败又与肿瘤干细胞有着密切的关系。肿瘤干细胞的耐药机制一般包括以下几个方面:高表达的ABC转运蛋白介导化疗药物外排;乙醛脱氢酶的高表达与肿瘤的发病率和预后差显著相关;高效的DNA损伤修复能力;促存活通路的激活能力。笔者综合介绍肿瘤干细胞几种主要的治疗耐受机制,以期为开发新型抗肿瘤药物以及临床合理用药提供理论依据。

English Abstract

曹梦雪, 孙凡, 林厚文. 肿瘤干细胞的治疗耐受机制研究进展[J]. 药学实践与服务, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
引用本文: 曹梦雪, 孙凡, 林厚文. 肿瘤干细胞的治疗耐受机制研究进展[J]. 药学实践与服务, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
Citation: CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001
参考文献 (35)

目录

    /

    返回文章
    返回